Stockscreener 앱 받기
372.18
3.18%
-12.22
전일 마감가:
$384.40
열려 있는:
$381.09
하루 거래량:
183.08K
Relative Volume:
0.79
시가총액:
$9.95B
수익:
$2.59B
순이익/손실:
$168.80M
주가수익비율:
61.27
EPS:
6.0748
순현금흐름:
$357.20M
1주 성능:
+0.60%
1개월 성능:
-1.46%
6개월 성능:
+32.86%
1년 성능:
+22.18%
1일 변동 폭
$368.44
$384.00
1주일 범위
$368.44
$390.15
52주 변동 폭
$236.73
$396.23
Bio Rad Laboratories Inc Stock (BIO) Company Profile
명칭
Bio Rad Laboratories Inc
전화
(510) 724-7000
주소
1000 ALFRED NOBEL DRIVE, HERCULES
Compare BIO vs ABT, MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
372.18 | 9.95B | 2.59B | 168.80M | 357.20M | 6.0748 |
ABT
Abbott Laboratories
|
106.20 | 183.77B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
96.54 | 123.49B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
291.86 | 111.95B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
41.98 | 60.84B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.01 | 53.03B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-05-15 | 재개 | RBC Capital Mkts | Outperform |
| 2026-04-07 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-10-01 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-08-28 | 개시 | Wells Fargo | Equal Weight |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2024-04-03 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-12-07 | 개시 | UBS | Buy |
| 2023-06-16 | 개시 | Wells Fargo | Overweight |
| 2022-12-07 | 개시 | RBC Capital Mkts | Outperform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-01-28 | 재확인 | Citigroup | Buy |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2018-10-17 | 개시 | Goldman | Buy |
| 2018-09-20 | 개시 | Morgan Stanley | Equal-Weight |
| 2018-02-16 | 다운그레이드 | CL King | Buy → Neutral |
| 2017-07-13 | 개시 | Wells Fargo | Outperform |
| 2017-06-28 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2017-01-18 | 개시 | Deutsche Bank | Hold |
| 2016-10-13 | 개시 | CL King | Buy |
| 2015-05-06 | 재확인 | Jefferies | Buy |
| 2009-12-18 | 개시 | Maxim Group | Buy |
| 2009-11-06 | 개시 | Jefferies & Co | Buy |
| 2009-07-17 | 개시 | Soleil | Buy |
| 2007-09-26 | 개시 | Banc of America Sec | Buy |
| 2007-02-23 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
모두보기
Bio Rad Laboratories Inc 주식(BIO)의 최신 뉴스
Bio-Rad Laboratories, Inc. Class B (BIO.B) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Bio-Rad Laboratories (BIO) Advances on Restructuring Plans and Margin Improvement Potential, Ariel Appreciation Fund Says - Yahoo Finance
Form 4 BIO-RAD LABORATORIES: Jonathan P. DiVincenzo (President & COO) For: 24 October - Investing.com UK
With awards vesting 25% yearly, Bio-Rad (BIO) COO acquires 1,869 shares. - Stock Titan
BIO (BIO) vs. TMO and DHR: Can Activist Pressure Close Bio-Rad’s Valuation Discount? - Yahoo Finance
Form 4 BIO-RAD LABORATORIES: Sedat Evran (EVP, Global Supply Chain) For: 20 October By Investing.com - Investing.com South Africa
Sedat Evran Reports Vesting of 1,044 Bio-Rad RSUs with Tax Share Disposal on October 20, 2026 - Kalkine Media
Bio-Rad Laboratories, Inc. Class B (BIO.B) Earnings Dates, Call Summary & Reports - TipRanks
Avoiding Lag: Real-Time Signals in (BIO) Movement - Stock Traders Daily
Quick ratio of Bio-Rad Laboratories, Inc. Class A – HAM:BUWA - TradingView
Bio-Rad Laboratories, Inc. (BIO) Stock Forecasts - Yahoo Finance
Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026 - Investing News Network
Liquidity Mapping Around (BIO) Price Events - Stock Traders Daily
Neogen (NEOG) Q1 Earnings and Revenues Beat Estimates - Zacks Investment Research
Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.
Bio-Rad Reports Second-Quarter 2026 Financial Results - Investing News Network
Europe Point of Care Diagnostics Market Size and Forecast, 20212031 | Market to Reach US$21.4 Billion by 2031 as Rapid Testing and Molecular Innovation Drive 13.4% CAGR - GlobeNewswire Inc.
Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR - GlobeNewswire Inc.
Magnetic Beads MarketGlobal Forecast and Growth Opportunities, 2026-2032 | Automation, Genomics, and Molecular Diagnostics Drive 7.91% CAGR Toward USD 6.18 Billion - GlobeNewswire Inc.
Bio-Rad Laboratories, Inc. (BIO) Stock Forecasts - Yahoo Finance
Avoiding Lag: Real-Time Signals in (BIO) Movement - Stock Traders Daily
North America Non-Viral Transfection Reagents Market Forecast to 2035 | Cell and Gene Therapy Demand Drives 8.5% CAGR and a USD 0.70 Billion Opportunity - GlobeNewswire Inc.
Bio-Rad Laboratories, Inc. Class A Revenue Breakdown – HAN:BUWA - tradingview.com
Bio-Rad Laboratories Inc Stock Intrinsic Values | HAM:BUWA - gurufocus.com
Bio-Rad Laboratories Inc Stock Baskets - gurufocus.com
Veterinary Diagnostics Market Size to Soar to USD 30.78 Billion by 2035 at a CAGR of 10.1%SNS Insider - GlobeNewswire Inc.
Global Therapeutic Drug Monitoring Consumables Market Forecast, 2026-2032AI-Enabled Automation and Integrated Lab Workflows Drive 8.22% CAGR, Lifting the Market to USD 586.85 Million by 2032 - GlobeNewswire Inc.
Weekly Recap: Bio-Rad growth and margin plan and digital PCR expansion - TradingView
Bio-Rad Laboratories, Inc. (BIO-B) Stock Price, News, Quote & History - Yahoo! Finance Canada
Bio-Rad at bernstein healthcare forum: shift toward profitable growth By Investing.com - Investing.com UK
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now - Zacks Investment Research
Global Metabolomics Market to Reach US$9.01 Billion by 2035 as Precision Medicine, Biomarker Discovery and Advanced Analytics Unlock New Opportunities - GlobeNewswire Inc.
Magnetic Bead Purification Kits Market Outlook 2026-2030: Investment Trends, Strategic Profiles and Revenue Share Outlook - GlobeNewswire Inc.
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum - Investing News Network
Bio-Rad Laboratories, Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
BIO-RAD LABORATORIES (NYSE: BIO) Grants 719 Derivative Securities to Director Allison Schwartz - Kalkine Media
BIO-RAD LABORATORIES Executive Evran Sedat Reports Exercising 3,880 Shares (NYSE: BIO) - Kalkine Media
Bio-Rad: Favorable Read-Across From Investor Event (NYSE:BIO) - Seeking Alpha
BIO-RAD LABORATORIES, INC. Executive Courtney C. Enloe Exercises 1,453 Stock Options at $0 (NYSE: BIO) - Kalkine Media
Bio-Rad (NYSE: BIO) director sees 320 RSUs convert, 116 shares withheld - Stock Titan
Bio-Rad (NYSE: BIO) EVP logs 4,313 RSU grant and 2,179 vested shares - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
1,453 stock units vest for Bio-Rad (NYSE: BIO) insider as 551 shares withheld - Stock Titan
Bio-Rad (NYSE: BIO) grants EVP 4,601 RSUs, with shares withheld at $386.11 - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com Canada
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com India
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com UK
Bio-Rad Terminates Forbes Tate Lobbying Pact - Legis1
Behavioral Patterns of BIO and Institutional Flows - Stock Traders Daily
Bio Rad Laboratories Inc (BIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bio Rad Laboratories Inc 주식 (BIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| EVRAN SEDAT | EVP, Global Supply Chain |
Oct 20 '26 |
Option Exercise |
0.00 |
1,044 |
0 |
4,647 |
| ENLOE COURTNEY C | EVP, General Counsel & Sec |
Sep 06 '26 |
Option Exercise |
0.00 |
768 |
0 |
1,957 |
| ENGELHARDT EVA ANETTE | EVP, President, CDG |
Sep 06 '26 |
Option Exercise |
0.00 |
1,152 |
0 |
2,313 |
| Lakkaraju Roop Kalyan | EVP, Chief Financial Officer |
Sep 06 '26 |
Option Exercise |
0.00 |
1,536 |
0 |
4,933 |
| Allison Schwartz | Director |
Sep 06 '26 |
Option Exercise |
0.00 |
92 |
0 |
1,768 |
| SCHWARTZ NORMAN D | Chairman & CEO |
Sep 06 '26 |
Option Exercise |
0.00 |
3,455 |
0 |
450,873 |
| EVRAN SEDAT | EVP, Global Supply Chain |
Sep 06 '26 |
Option Exercise |
0.00 |
864 |
0 |
3,880 |
| BARRY JAMES | EVP, President, LSG |
Sep 06 '26 |
Option Exercise |
0.00 |
1,056 |
0 |
2,495 |
| Lakkaraju Roop Kalyan | EVP, Chief Financial Officer |
Sep 05 '26 |
Option Exercise |
0.00 |
1,370 |
0 |
3,956 |
| SCHWARTZ NORMAN D | Chairman & CEO |
Sep 05 '26 |
Option Exercise |
0.00 |
4,109 |
0 |
450,294 |
4.22%
1.85%
자본화:
|
볼륨(24시간):